

Nectar Lifesciences Ltd.

Ref. No.: NLL/CS/2022-158



August 13, 2022

National Stock Exchange of India Limited
Listing Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai 400 051
Symbol: NECLIFE

BSE Limited
Corporate Relationship Department,
P J Towers, Dalal Street,
Mumbai 400 001
Scrip Code: 532649

Ref.: Compliance of Regulations 30, 33 and other applicable regulations of Securities and Exchange Board of India (Listing Obligations & Disclosures Requirements) Regulations, 2015 ('LODR Regulations').

Sub.: Unaudited Financial Results and outcome of Board Meeting

Dear Sir/Madam,

We wish to inform you that the Board of Directors in their meeting held on August 13, 2022 have inter-alia decided and approved the following matters:

1. Approved and took on record the limited reviewed Unaudited Standalone & Consolidated Financial results for the quarter ended on June 30, 2022, which are enclosed herewith along with the Limited Review Reports of the Auditors thereon.
2. Approved to appoint Dr. Sanjit Singh Lamba (DIN 01741827) as an Additional Director on the Board.

He has also been appointed as a Wholetime Director designated as Director (Technical) of the company for a period of 2 years.

Profile: Dr. Sanjit Singh Lamba, aged 56 years, has completed his Bachelors from Panjab University, Chandigarh, Masters in Pharmaceutical Technology from Panjab University, Chandigarh, PGDMS from Mumbai University and is a Scholar Ph.D. in Pharm Technology from Gitam University, Vizag.

Named thrice in the list of "100 of the most inspiring People" in the Lifesciences industry by PhramaVOICE, USA, Dr. Lamba has more than 33 years of experience in the pharmaceutical industry. His Core skills and competence include Global Regulatory Compliance, Change Management, P&L Management, Quality management, Plant Operations, Operational



Nectar Lifesciences Ltd.



Excellence, SME for Sterile Products, Contract Manufacturing, Custom Manufacturing, Pilot Scale development and Cost Optimization etc.

He is associated with professional bodies like Indian Pharmaceutical Association, International Society for Pharmaceutical Engineers (ISPE). He also served as Past Chair – India Chapter for Parental Drug Association (PDA) and past Chairman - Technical & Supply Chain Committee for Organization of Pharmaceutical Producers of India (OPPI). He is also a Judging member for ISPE FOYA, USA.

He has certified that:

- i) He is not disqualified to become a Director under the Companies Act, 2013 and not debarred from holding the office of Director by virtue of any Securities & Exchange Board of India Order or any other such authority.
- ii) He does not hold any equity share in the company.
- iii) He does not have any relationship with any other director of the company

The Company also confirms the contents at point no. i. of the above para.

3. Approved to propose to the members in the forthcoming Annual General Meeting to be held on September 21, 2022 ("AGM") to:

- i. Appoint Dr. Indu Pal Kaur (DIN 09686862) on the Board as a regular Independent Director of the company. Her appointment as an Additional (Independent) Director on the Board of Nectar Lifesciences Limited had already been intimated to the stock exchanges vide letter *Ref: NLL/CS/2022-153* dated August 03, 2022.
- ii. Appoint Dr. Sanjit Singh Lamba as a regular Director liable to retire by rotation.
- iii. Approve the appointment Dr. Sanjit Singh Lamba as a Whole time Director designated as a Director (Technical)

The Board meeting commenced at 12:00 P.M. and concluded at 1:30 P.M.

This is for your kind information and record please.

Thanking you,
Yours Sincerely,

For **Nectar Lifesciences Limited**

(Anubha)

Company Secretary

